Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Immunogenicity Study of GSK Biologicals' Candidate Tuberculosis Vaccine (692342) When Administered to Healthy HIV-negative Adolescents Living in a TB Endemic Region

NCT00950612 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00950612
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00950612 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Immunogenicity Study of GSK Biologicals' Candidate Tuberculosis Vaccine (692342) When Administered to Healthy HIV-negative Adolescents Living in a TB Endemic Region
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Completed
Start date
December 8, 2009
Completion date
September 30, 2010
Enrollment
60 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

tuberculosis